TABLE 2.
AE | Keverprazan 20 mg | Keverprazan 40 mg | Vonoprazan 20 mg | Placebo |
---|---|---|---|---|
N | 8 | 8 | 4 | 6 |
Any | 3 (37.50%) | 6 (75.00%) | 2 (50.00%) | 3 (50.00%) |
TRAE | 2 (25.00%) | 2 (25.00%) | 2 (50.00%) | 3 (50.00%) |
SAE | 0 | 0 | 0 | 0 |
AE leading to study discontinuation | 1 (12.50%) | 0 | 0 | 0 |
Abbreviations: AE, adverse event; SAE, severe adverse event; TRAE: treatment‐related adverse event.